KRAZATI ratings & reviews

Adagrasib
Company: BMS
Brand: KRAZATI
Drug class: Antineoplastic and Immunomodulating Agents
+2 more
Antineoplastic and Immunomodulating Agents, Antineoplastics, Small Molecule Antineoplastic KRAS G12C Inhibitors
Overall rating
3.4
full star full star full star empty star empty star
Ranked #11
Physician ratings
  • Efficacy: effective for its intended use
  • Safety: safe to use in humans
  • Tolerability: low drug side effects
  • Accessibility: insurance/payer coverage, cost, affordability,formulary coverage, availability in your hospital or practice setting
  • Adherence: patient compliance with treatment
Efficacy
3.7/5
Safety
3.4/5
Tolerability
3.4/5
Accessibility
3.1/5
Adherence
3.3/5

Sermo AI Overview

  • KRAZATI shows strong efficacy in treating colorectal cancer, particularly for patients who've exhausted other treatment options, achieving a general efficacy rating of 4 out of 5. However, overall feedback from healthcare professionals reveals mixed views on its tolerability and accessibility.
  • In the treatment of non-small cell lung cancer, KRAZATI is highly rated by physicians for its efficacy and safety, frequently receiving perfect scores. Yet, challenges with accessibility in certain regions may restrict its wider use among patients.
  • Patients using KRAZATI may encounter side effects like diarrhea, nausea, and vomiting, prompting the need for careful monitoring of potential drug interactions, which is crucial for ensuring patient safety during treatment.
  • In specific contexts, like India, KRAZATI's performance is viewed less favorably, often considered only when other options have failed, leading to an overall score of 3 out of 5, which highlights varying perceptions of its effectiveness.
  • Was this summary helpful?
Based on insights from Sermo’s triple verified physicians

Description

KRAZATI is a tablet containing adagrasib as the active ingredient in a 200 mg dosage. Adagrasib is an irreversible inhibitor of KRAS G12C and part of the RAS GTPase family. It is formulated as a tablet for oral administration, with inactive ingredients such as colloidal silicon dioxide, crospovidone, and magnesium stearate. KRAZATI is intended for oral use with additional coatings that include hypromellose and titanium dioxide.

Source: This information is sourced from FDA and powered by AI

Dosage & Administration

How should I use this medication?

Take this medication by mouth. Take it as directed on the prescription label at the same time every day. Do not cut, crush, or chew this medication. Swallow the tablets whole. You can take it with or without food. If it upsets your stomach, take it with food. Your care team may change your dose or tell you to stop taking this medication if you get side effects. Do not change your dose or stop taking it unless your care team tells you to.

Do not take this medication with grapefruit juice during the first 8 days of therapy.

Talk to your care team about the use of this medication in children. Special care may be needed.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

If you miss a dose, take it as soon as you can unless it is more than 4 hours late. If it is more than 4 hours late, skip the missed dose. Take the next dose at the normal time.

Where should I keep my medication?

Keep out of the reach of children and pets.

Store at room temperature between 20 and 25 degrees C (68 and 77 degrees F). Protect from moisture. Keep the container tightly closed. Do not throw out the packet in the container. It keeps the medication dry. Get rid of any unused medication after the expiration date.

To get rid of medications that are no longer needed or have expired:

  • Take the medication to a medication take-back program. Check with your pharmacy or law enforcement to find a location.
  • If you cannot return the medication, check the label or package insert to see if the medication should be thrown out in the garbage or flushed down the toilet. If you are not sure, ask your care team. If it is safe to put in the trash, take the medication out of the container. Mix the medication with cat litter, dirt, coffee grounds, or other unwanted substance. Seal the mixture in a bag or container. Put it in the trash.

NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.

Side Effects

What side effects may I notice from receiving this medication?

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Bowel blockage—stomach cramping, unable to have a bowel movement or pass gas, loss of appetite, vomiting
  • Dry cough, shortness of breath or trouble breathing
  • Heart rhythm changes—fast or irregular heartbeat, dizziness, feeling faint or lightheaded, chest pain, trouble breathing
  • Kidney injury—decrease in the amount of urine, swelling of the ankles, hands, or feet
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue
  • Stomach bleeding—bloody or black, tar-like stools, vomiting blood or brown material that looks like coffee grounds
  • Sudden or severe stomach pain, bloody diarrhea, fever, nausea, vomiting

Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):

  • Diarrhea
  • Fatigue
  • Loss of appetite
  • Muscle pain
  • Nausea
  • Vomiting

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Warnings & Precautions

What should I tell my care team before I take this medication?

They need to know if you have any of these conditions:

  • Heart disease
  • Irregular heartbeat or rhythm
  • Liver disease
  • Lung disease
  • Stomach or intestine problems
  • An unusual or allergic reaction to adagrasib, other medications, foods, dyes, or preservatives
  • Pregnant or trying to get pregnant
  • Breast-feeding

What may interact with this medication?

Do not take this medication with any of the following:

  • Alfuzosin
  • Alprazolam
  • Certain medications for cholesterol, such as lovastatin, simvastatin, lomitapide
  • Certain medications for fungal infections, such as fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole
  • Certain medications for migraine headaches, such as eletriptan, ubrogepant
  • Cisapride
  • Conivaptan
  • Dronedarone
  • Eliglustat
  • Ergot alkaloids, such as dihydroergotamine, ergotamine
  • Finerenone
  • Flibanserin
  • Isavuconazonium
  • Ivabradine
  • Lonafarnib
  • Lopinavir
  • Lurasidone
  • Mavacamten
  • Naloxegol
  • Pacritinib
  • Pimozide
  • Ranolazine
  • Saquinavir
  • Silodosin
  • Thioridazine
  • Tolvaptan
  • Triazolam
  • Voclosporin

This medication may also interact with the following:

  • Dextromethorphan
  • Digoxin
  • Midazolam
  • Other medications that cause heart rhythm changes
  • Rifampin
  • Warfarin

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medication?

This medication may make you feel generally unwell. This is not uncommon as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your care team tells you to stop.

If you get black, tarry stools or vomit up what looks like coffee grounds, call your care team right away.

This medication may cause infertility. Talk to your care team if you are concerned about your fertility.

Do not breast-feed while taking this medication and for 1 week after stopping treatment.

Source: This information is sourced from Elsevier Inc.

Disclaimer

The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.

Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.

Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.

Terms of use

  1. Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool). 

  2. Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc.  Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”).  Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.

  3. Authorized User acknowledges and agrees that the Elsevier Products are designed for and are intended to be used by those residing in the United States, and that the information contained in the Elsevier Products does not comply with any laws or practices outside of the United States. You assume all responsibilities, duties, and obligations for any treatment, decision, or advice made or given to third parties as a result of the use or application of the Elsevier Products outside of the United States, and Sermo, Elsevier and its affiliates, subsidiaries, agents and suppliers will incur no liability for any use or application of the Products by Authorized Users outside of the United States.

Welcome to Sermo's Drug Ratings

Previously only for members, Sermo Drug Ratings are now openly available to all healthcare providers, patients, and industry professionals to support better healthcare decisions.

Clinical expertise
Insights based on real prescribing experience from triple-verified practicing physicians only
Detailed insights
Ratings on key attributes including efficacy, safety, tolerability, accessibility, and adherence
Unbiased reviews
Independent, physician-only reviews, free from pharmaceutical industry influence